| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/23/2000 | EP0980358A1 Pharmacological agents |
| 02/23/2000 | EP0980273A1 Biodegradable osteosynthesis implant |
| 02/23/2000 | EP0980263A1 Combined product associating a nucleic acid with a substance breaking up the extracellular matrix for gene therapy |
| 02/23/2000 | EP0980259A1 Use of a cd40:cd154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection |
| 02/23/2000 | EP0980258A1 Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy |
| 02/23/2000 | EP0980255A2 Adhesion prevention and an endoscopic insufflation system therefor |
| 02/23/2000 | EP0980254A1 Pharmaceutical antiviral composition comprising glycyrrhizic acid and at least one protein endowed with antiviral activity |
| 02/23/2000 | EP0980251A1 Tissue factor for influencing blood vessel formation |
| 02/23/2000 | EP0980249A1 Use of cd26 inhibitor for the manufacture of a medicament for the treatment of hiv |
| 02/23/2000 | EP0980247A1 Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain |
| 02/23/2000 | EP0980245A1 Use of misoprostol or/and misoprostol acid for preparing drug in order to cure erectile dysfunction |
| 02/23/2000 | EP0980205A1 Method of treating malignancies |
| 02/23/2000 | EP0980203A1 Antimicrobial prevention and treatment of human immunedeficiency virus and other infectious diseases |
| 02/23/2000 | CN1245536A Novel calpaines, production and use thereof |
| 02/23/2000 | CN1245423A Formulation and method for treating neoplasms by inhalation |
| 02/22/2000 | US6028222 Stable liquid paracetamol compositions, and method for preparing same |
| 02/22/2000 | US6028164 Bioresorbable compositions for implantable prostheses |
| 02/22/2000 | US6028114 Use of aminothiolester derivatives in pharmaceutics |
| 02/22/2000 | US6028070 Treating oppositional defiant disorder comprising administration to a patient in need of such treatment an effective amount of a norepinephrine reuptake inhibitor selective for norepinephrine over other neurotransmitters |
| 02/22/2000 | US6028058 Methods and compositions for regulating nuclear trafficking of proteins |
| 02/22/2000 | US6028054 Method for increasing bioavailability of oral pharmaceutical compositions |
| 02/22/2000 | US6028052 Treating NIDDM with RXR agonists |
| 02/22/2000 | US6027935 Gene up-regulated in regenerating liver |
| 02/22/2000 | US6027905 Methods for the detection of cervical cancer |
| 02/22/2000 | CA2179627C Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread |
| 02/22/2000 | CA2003455C Immunotherapy involving cd28 stimulation |
| 02/17/2000 | WO2000008199A1 Molecular cloning of a 7tm receptor (gpr31a) |
| 02/17/2000 | WO2000008179A1 Ikr-1 and ikr-2, protein kinases which are related to the i kappa b kinases |
| 02/17/2000 | WO2000008177A2 Death associated kinase containing ankyrin repeats (dakar) |
| 02/17/2000 | WO2000008171A1 N-acetylglycosaminyl transferase genes |
| 02/17/2000 | WO2000008147A1 Genes involved in the molecular paths for tumour suppression and /or resistance to viruses |
| 02/17/2000 | WO2000008144A1 Dna encoding a human inhibitor-of-apoptosis protein; hiap3 |
| 02/17/2000 | WO2000007624A2 Pharmaceutical composition having inhibitory effect on overproduction and accumulation of extracellular matrix |
| 02/17/2000 | WO2000007620A1 Protease inhibitors for use in the treatment of psoriasis |
| 02/17/2000 | WO2000007619A1 Alteration of the cell cycle in vivo, and particularly for inducing apoptosis of tumor cells |
| 02/17/2000 | WO2000007618A2 Anti-apoptotic compositions comprising the r1 subunit of herpes simplex virus ribonucleotide reductase or its n-terminal portion; and uses thereof |
| 02/17/2000 | WO2000007617A1 Use of glp-1 and analogues for preventing type ii diabetes |
| 02/17/2000 | WO2000007616A2 Use of novel agents inducing cell death in synergy with interferons |
| 02/17/2000 | WO2000007605A1 Use of camptothecin derivatives, with reduced gastrointestinal toxicity |
| 02/17/2000 | WO2000007604A1 Prostate formula |
| 02/17/2000 | WO2000007600A1 Pharmaceutical compositions for the prevention and treatment of central nervous system disorders |
| 02/17/2000 | WO2000007599A1 Prevention of endometriosis signs or symptoms |
| 02/17/2000 | WO2000007598A1 Use of a nk-1 receptor antagonist for treating or preventing abnormal bone resorption |
| 02/17/2000 | WO2000007597A1 Transmucosal therapeutic system for administering sildenafil |
| 02/17/2000 | WO2000007596A1 Water-soluble pharmaceutical formulation for administering sildenafil |
| 02/17/2000 | WO2000007581A2 Antioxidant, antiproliferous composition, comprising a carnitine and a carotenoid |
| 02/17/2000 | WO2000007576A2 INHIBITORS OF TYPE 3 3α-HYDROSTEROID DEHYDROGENASE |
| 02/17/2000 | WO2000007566A1 A new analgesic, anti-inflammatory and wound healing agent |
| 02/17/2000 | WO2000007549A1 Finely dispersed emulsifier-free systems of the oil-in-water and water-in-oil type, containing boron nitride |
| 02/17/2000 | WO2000007548A1 Finely dispersed emulsifier-free systems of the oil-in-water and water-in-oil type |
| 02/17/2000 | WO2000007544A2 Vitronectin receptor antagonists |
| 02/17/2000 | WO2000007543A2 Conjugates targeted to the interleukin-2 receptors |
| 02/17/2000 | WO2000007542A2 Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance p |
| 02/17/2000 | WO2000007515A1 Improved method for targeted topical treatment of disease |
| 02/17/2000 | WO1999062534B1 IL-6/sIL-6R COMPLEX FOR PROMOTION OF LIVER FUNCTIONS |
| 02/17/2000 | WO1999058126B1 Use of neomycin for treating angiogenesis-related diseases |
| 02/17/2000 | WO1999056763A9 Use of neglected target tissue antigens in modulation of immune responses |
| 02/17/2000 | WO1999050461A9 Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis |
| 02/17/2000 | WO1999020261A3 Use of antigunal agents for the topial treatment of fungus-induced mucositis |
| 02/17/2000 | WO1999015159A3 Methods for increasing apoe levels for the treatment of neurodegenerative disease |
| 02/17/2000 | DE19836044A1 New 2-(hetero)aryl-alkanoic acid derivatives, useful as mixed endothelin receptor antagonists, e.g. for treating cardiac insufficiency, restenosis, hypertension or prostate cancer |
| 02/17/2000 | CA2348637A1 A new analgesic, anti-inflammatory and wound healing agent |
| 02/17/2000 | CA2340020A1 Use of camptothecin derivatives, with reduced gastrointestinal toxicity |
| 02/17/2000 | CA2339666A1 Vitronectin receptor antagonists |
| 02/17/2000 | CA2339485A1 Protease inhibitors for use in the treatment of psoriasis |
| 02/17/2000 | CA2339368A1 Inhibitors of type 3 3.alpha.-hydroxysteroid dehydrogenase |
| 02/17/2000 | CA2339352A1 N-acetylglycosaminyltransferase genes |
| 02/17/2000 | CA2339322A1 Genes involved in the molecular paths for tumour suppression and /or resistance to viruses |
| 02/17/2000 | CA2339146A1 Use of a nk-1 receptor antagonist for treating or preventing abnormal bone resorption |
| 02/17/2000 | CA2339086A1 Dna replication- and repair-associated proteins |
| 02/17/2000 | CA2339085A1 Conjugates targeted to the interleukin-2 receptors |
| 02/17/2000 | CA2338385A1 Human receptor-associated proteins |
| 02/17/2000 | CA2338035A1 Antioxidant, antiproliferous composition, comprising a carnitine and a carotenoid |
| 02/17/2000 | CA2305680A1 Death associated kinase containing ankyrin repeats (dakar) |
| 02/16/2000 | EP0979870A1 Human Wnt-6 polypeptide |
| 02/16/2000 | EP0979650A1 Antiviral agents |
| 02/16/2000 | EP0979289A1 Human lysophospholipase |
| 02/16/2000 | EP0979284A2 Methods and reagents for vaccination which generate a cd8 t cell immune response |
| 02/16/2000 | EP0979280A1 Polynucleotides encoding a cd53-like transmembrane protein |
| 02/16/2000 | EP0979275A1 Novel human mago nashi protein |
| 02/16/2000 | EP0979274A2 Human p24 vesicle proteins |
| 02/16/2000 | EP0979273A1 MODIFIED ANTISENSE NUCLEOTIDES COMPLEMENTARY TO A SECTION OF THE HUMAN Ha-Ras GENE |
| 02/16/2000 | EP0979225A1 Compounds and compositions for delivering active agents |
| 02/16/2000 | EP0979105A1 Topical nasal antiinflammatory compositions |
| 02/16/2000 | EP0979100A1 ANTI-$i(HELICOBACTER) VACCINE COMPOSITION COMPRISING A TH1 ADJUVANT |
| 02/16/2000 | EP0979099A1 Use of lactoferin in the treatment of allergen induced disorders |
| 02/16/2000 | EP0979098A1 Method of treating hyperprolactinemia and prolactinomas |
| 02/16/2000 | EP0979096A1 Treatment of infarcts through inhibition of nf-kappab |
| 02/16/2000 | EP0979093A1 Arrestable therapeutic viral agent |
| 02/16/2000 | EP0979092A2 Allelic polygene diagnosis of reward deficiency syndrome and treatment |
| 02/16/2000 | EP0979090A1 Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and s-adenosylmethionine |
| 02/16/2000 | EP0979089A1 Methods for using macrocyclic lactone compounds as multidrug resistance reversing agents in tumor and other cells |
| 02/16/2000 | EP0979087A1 Analgesic combination |
| 02/16/2000 | EP0979086A2 Method and composition for modulating amyloidosis |
| 02/16/2000 | EP0979082A1 Antiviral combinations containing the carbocyclic nucleoside 1592u89 |
| 02/16/2000 | EP0979081A1 Composition and methods using an eutomer |
| 02/16/2000 | EP0979080A1 A method of modulating an immune response in an infected mammal by transmucosal administration of modulating agent |
| 02/16/2000 | CN1244921A Treatment and diagnosis of cancer |
| 02/16/2000 | CN1244803A Soluble CTLA4 mutant molecules and uses thereof |
| 02/16/2000 | CN1244796A Pellets having a core coated with an antifungal and a polymer |